Dr. Harini Srinivasan is a Principal Scientific Associate at Serna Bio with over 10 years of research experience in academic institutions, health care organizations and pharmaceutical companies. With a background in Bioinformatics and Computational Biology, she has a keen interest in using technology to solve problems in healthcare and medicine.

Harini joined Serna Bio in early 2021 and has been an integral part of the multidisciplinary teamworking on target ID platform development to drug discovery. She has played a key role inbuilding the target identification platform and a proprietary database of transcriptome-wide, functional RNA structures. She leads the development of robust computational pipelines for analyzing the functional datasets that play a crucial role in identifying key target-compound pairs for progression towards drug discovery.

Over the course of her career, Dr. Srinivasan has led the development of multiple computational pipelines to process data from different next generation sequencing techniques with applications in oncology, genome editing systems including CRISPR-Cas mediated DNA editing, and ADAR-mediated RNA editing. She also has experience looking at the biomolecular systems at an atomistic level to model them, understand their functioning and identify potential ways to modulate them. Dr Srinivasan is passionate about continuous learning as is evidenced by her dynamic career, which has resulted in expertise ranging from studying biomolecular systems at an atomistic level to working with big data from high-throughput single-cell technologies. In her current role at Serna Bio, she utilizes her rich experiences from both these domains and is taking another step towards her goal of using her skills to impact patient care.

My name is Miguel, and I’m from Murcia, Spain. I pursued a degree in Pharmacy from the University of Murcia to become a qualified Pharmacist, followed by an MSc in Cancer Pharmacology at London Metropolitan University. During my studies, I had the exciting opportunity to work at The Francis Crick Institute’s Enchev Lab, exploring RecA recombinase kinetics through innovative techniques like time-resolved Cryo-EM and single molecule fluorescence.

Driven by an interest in structural biochemistry and drug discovery (DD), I joined AstraZeneca in 2019. Rising from Research Scientist to Senior Scientist, I supported early-stage DD efforts within their Protein Science group, based in Cambridge, UK. My role involved generating and characterizing complex proteins critical for biological assay development, hit discovery, and structural biology. During this time, I had the opportunity to step in as an interim Discovery Sciences project lead, sparking my interest in project leadership.

Fascinated by the potential of AI in medical research, I transitioned to BenevolentAI in early 2023 as a Biology Project Leader. There, I supported AI-enabled DD efforts in their small molecule portfolio. This involved designing and implementing biological strategies, encompassing target validation, hit identification, establishing assays, and collaborating on structural work.

Joining Isomorphic Labs in October 2024, I’m thrilled to be part of their mission to revolutionize DD through AI/ML. Inspired by AlphaFold’s achievements, Isomorphic Labs aims to reimagine the entire process, ultimately benefiting patients worldwide. As a Research Investigator, I lead the biology domain of Iso’s DD programs. Here, I collaborate closely with diverse scientific disciplines and the tech team to unlock the power of cutting-edge advancements, driving a unified and efficient approach to DD.

Miles graduated from the University of Nottingham with an MSci degree in Chemistry in 2021, after completing his final year project with Dr. Andrew Teale using computational methods to explore the structure of molecules under strong magnetic fields.

After graduating, Miles went on to work as a scientist on AstraZeneca’s Research and Development graduate programme, working on projects in biocatalysis, computational organic chemistry and machine learning for drug discovery.

Miles is now completing his MRes year as part of the Accountable, Responsible and Transparent AI Integrated PhD programme at the University of Bath, where he will go on to complete his PhD under the supervision of Dr. Matthew Grayson.

His current research concerns the use of quantum chemistry and machine learning to understand chemical reactivity, with the aim of providing insights into the most widely used reaction classes in pharmaceutical synthesis and enabling chemists to design and optimise new synthetic routes to molecules.

Janne has nearly 25 years of experience in recruitment, having hired across Tech and Life Sciences. Her current position in SRG as an SME in roles encompassing Computational Biology, Artificial Intelligence, and Machine Learning when applicable to the world of healthcare reflects her expertise. Janne is driven by finding the perfect match for company and candidate to ensure a high level of employee retention. From small start-ups through to big pharma, Janne’s experience covers it all.

Janne’s passion for the topic of ethics and the future of AI has led her to attend conferences and events to build her knowledge as an attendee and be invited to panels and fireside chats to discuss. Her involvement in a number of Biotech start-up accelerator programs speaks to her commitment to innovation.

Jasmine is currently a member of the ELRIG’s Early Careers Professionals (ECP) workgroup, which aims to enhance ECP engagement in the ELRIG network via targeted events, opportunities, and knowledge.

In her day job, she is a Scientist at Sartorius within the Bio Analytic Applications team. She is involved in the research and development of cellular assays across multiple research areas for live-cell analysis applications, including AI-based image analysis tools.

Jasmine has a background in neuroscience and genetic manipulation, with early works focused on using a combined structural and molecular biology approach to assess disease-associated proteins implicated in Alzheimer’s disease.

Millie graduated from the University of Sussex with a Biochemistry degree in 2016, which included an industrial placement year at GSK, Stevenage. Inspired by her time at GSK, Millie pursued a PhD at the University of Cambridge investigating the signalling pathways that drive cancer cell growth using in-vitro cell based assays and biochemical analysis.

Driven by an interest in drug discovery Millie joined AstraZeneca after completion of her PhD at the end of 2020. She is currently a Senior drug discovery scientist working across Cell Engineering, Cell Biology and Functional Genomics teams, using CRISPR/Cas9 and Next Generation Sequencing for target identification, target validation and drug development in the oncology disease area.

As an early career professional (ECP) herself, Millie is currently a member of ELRIG’s ECP workgroup, and is excited to co-chair her first webinar.